<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1003221840
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        COAPROVEL 300-12.5 MG TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        IRBESARTAN,HYDROCHLOROTHIAZIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        300,12.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        77
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SANOFI WINTHROP INDUSTRIE" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SANOFI WINTHROP INDUSTRIE
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2218]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Sanofi Arabia Trading Co. Ltd
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Sanofi Clir SNC
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09DA04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>CoAprovel is a combination of two active substances, irbesartan and hydrochlorothiazide.<br />Irbesartan belongs to a group of medicines known as angiotensin-II receptor antagonists.<br />Angiotensin-II is a substance produced in the body that binds to receptors in blood vessels<br />causing them to tighten. This results in an increase in blood pressure. Irbesartan prevents<br />the binding of angiotensin-II to these receptors, causing the blood vessels to relax and the<br />blood pressure to lower.<br />Hydrochlorothiazide is one of a group of medicines (called thiazide diuretics) that causes<br />increased urine output and so causes a lowering of blood pressure.<br />The two active ingredients in CoAprovel work together to lower blood pressure further than if<br />either was given alone.<br />CoAprovel is used to treat high blood pressure, when treatment with irbesartan or<br />hydrochlorothiazide alone did not provide adequate control of your blood pressure.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Contraindications:<br />Do not take CoAprovel<br />▪ if you are allergic to irbesartan or any of the other ingredients of this medicine (listed in<br />section 6)<br />▪ if you are allergic to hydrochlorothiazide or any other sulfonamide-derived medicines</p><p>▪ if you are more than 3 months pregnant. (It is also better to avoid CoAprovel in early pregnancy &ndash; see pregnancy section)<br />▪ if you have severe liver or kidney problems<br />▪ if you have difficulty in producing urine<br />▪ if your doctor determines that you have persistently high calcium or low potassium levels in your blood<br />▪ if you have diabetes or impaired kidney function and you are treated with a blood pressure lowering medicine containing aliskiren.<br />Appropriate precautions for use; special warnings:<br />Warning and precautions<br />Talk to your doctor before taking CoAprovel and if any of the following apply to you:<br />▪ if you get excessive vomiting or diarrhoea<br />▪ if you suffer from kidney problems or have a kidney transplant<br />▪ if you suffer from heart problems<br />▪ if you suffer from liver problems<br />▪ if you suffer from diabetes<br />▪ if you suffer from lupus erythematosus (also known as lupus or SLE)<br />▪ if you suffer from primary aldosteronism (a condition related to high production of the hormone aldosterone, which causes sodium retention and, in turn, an increase in blood pressure).<br />▪ if you are taking any of the following medicines used to treat high blood pressure:<br />▪ an ACE-inhibitor ( for example enalapril, lisinopril, ramipril) in particular if you have diabetes-related kidney problems.<br />▪ aliskiren.<br />▪ if you have had skin cancer or if you develop an unexpected skin lesion during the treatment. Treatment with hydrochlorothiazide, particularly long term use with high doses, may increase the risk of some types of skin and lip cancer (non-melanoma skin cancer). Protect your skin from sun exposure and UV rays while taking CoAprovel<br />Your doctor may check your kidney function, blood pressure, and the amount of electrolytes (e.g. potassium) in your blood at regular intervals.<br />See also information under the heading &ldquo;Do not take CoAprovel&rdquo;.<br />You must tell your doctor if you think you are (or might become) pregnant. CoAprovel is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see pregnancy section).<br />You should also tell your doctor:<br />▪ if you are on a low-salt diet<br />▪ if you have signs such as abnormal thirst, dry mouth, general weakness, drowsiness, muscle pain or cramps, nausea, vomiting, or an abnormally fast heart beat which may indicate an excessive effect of hydrochlorothiazide (contained in CoAprovel)<br />▪ if you experience an increased sensitivity of the skin to the sun with symptoms of sunburn (such as redness, itching, swelling, blistering) occurring more quickly than normal<br />▪ if you are going to have an operation (surgery) or be given anaesthetics<br />▪ if you have changes in your vision or pain in one or both of your eyes while taking CoAprovel. This could be a sign that you are developing glaucoma, increased</p><p>pressure in your eye(s). You should discontinue CoAprovel treatment and seek medical attention.<br />The hydrochlorothiazide contained in this medicine could produce a positive result in an anti-doping test.<br />Children and adolescents<br />CoAprovel should not be given to children and adolescents (under 18 years).<br />Other medicines and CoAprovel<br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.<br />Diuretic agents such as the hydrochlorothiazide contained in CoAprovel may have an effect on other medicines. Preparations containing lithium should not be taken with CoAprovel without close supervision by your doctor.<br />Your doctor may need to change your dose and/or to take other precautions:<br />If you are taking an ACE-inhibitor or aliskiren (see also information under the headings &ldquo;Do not take CoAprovel&rdquo; and &ldquo;Warnings and precautions&rdquo;).<br />You may need to have blood checks if you take:<br />▪ potassium supplements<br />▪ salt substitutes containing potassium<br />▪ potassium sparing medicines or other diuretics (water tablets)<br />▪ some laxatives<br />▪ medicines for the treatment of gout<br />▪ therapeutic vitamin D supplements<br />▪ medicines to control heart rhythm<br />▪ medicines for diabetes (oral agents or insulins)<br />▪ carbamazepine (a medicine for the treatment of epilepsy).<br />It is also important to tell your doctor if you are taking other medicines to reduce your blood pressure, steroids, medicines to treat cancer, pain killers, arthritis medicines, or colestyramine and colestipol resins for lowering blood cholesterol.</p><p>CoAprovel with food and drink<br />CoAprovel can be taken with or without food.<br />Due to the hydrochlorothiazide contained in CoAprovel, if you drink alcohol while on treatment with this medicine, you may have an increased feeling of dizziness on standing up, specially when getting up from a sitting position.<br /><strong>Pregnancy, breast-feeding and fertility</strong><br /><strong>Pregnancy</strong><br />You must tell your doctor if you think you are (or might become) pregnant. Your doctor will normally advise you to stop taking CoAprovel before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of CoAprovel. CoAprovel is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy.</p><p><strong>Breast-feeding</strong><br />Tell your doctor if you are breast-feeding or about to start breast-feeding. CoAprovel is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is newborn, or was born prematurely.<br /><strong>Driving and using machines</strong><br />CoAprovel is unlikely to affect your ability to drive or use machines. However, occasionally dizziness or weariness may occur during treatment of high blood pressure. If you experience these, talk to your doctor before attempting to drive or use machines.<br /><strong>CoAprovel contains lactose.</strong> If you have been told by your doctor that you have an intolerance to some sugars (e.g. lactose), contact your doctor before taking this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.<br /><strong>Dosage</strong><br />The recommended dose of CoAprovel is one tablet a day. CoAprovel will usually be prescribed by your doctor when your previous treatment did not reduce your blood pressure enough. Your doctor will instruct you how to switch from the previous treatment to CoAprovel.<br /><strong>Method of administration</strong><br />CoAprovel is for oral use. Swallow the tablets with a sufficient amount of fluid (e.g. one glass of water). You can take CoAprovel with or without food. Try to take your daily dose at about the same time each day. It is important that you continue to take CoAprovel until your doctor tells you otherwise.<br />The maximal blood pressure lowering effect should be reached 6-8 weeks after beginning treatment.<br /><strong>If you take more CoAprovel than you should</strong><br />If you accidentally take too many tablets, contact your doctor immediately.<br /><strong>Children should not take CoAprovel</strong><br />CoAprovel should not be given to children under 18 years of age. If a child swallows some tablets, contact your doctor immediately.<br /><strong>If you forget to take CoAprovel</strong><br />If you accidentally miss a daily dose, just take the next dose as normal. Do not take a double dose to make up for a forgotten dose.<br />If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />Some of these effects may be serious and may require medical attention.</p><p>Rare cases of allergic skin reactions (rash, urticaria), as well as localised swelling of the face, lips and/or tongue have been reported in patients taking irbesartan.<br />If you get any of the above symptoms or get short of breath, stop taking CoAprovel and contact your doctor immediately.<br />The frequency of the side effects listed below is defined using the following convention:<br />Common: may affect up to 1 in 10 people<br />Uncommon: may affect up to 1 in 100 people<br />Side effects reported in clinical studies for patients treated with CoAprovel were:<br />Common side effects (may affect up to 1 in 10 people):<br />▪ nausea/vomiting<br />▪ abnormal urination<br />▪ fatigue<br />▪ dizziness (including when getting up from a lying or sitting position)<br />▪ blood tests may show raised levels of an enzyme that measures the muscle and heart function (creatine kinase) or raised levels of substances that measure kidney function (blood urea nitrogen, creatinine).<br />If any of these side effects causes you problems, talk to your doctor.<br />Uncommon side effects (may affect up to 1 in 100 people):<br />▪ diarrhoea<br />▪ low blood pressure<br />▪ fainting<br />▪ heart rate increased<br />▪ flushing<br />▪ swelling<br />▪ sexual dysfunction (problems with sexual performance)<br />▪ blood tests may show lowered levels of potassium and sodium in your blood.<br />If any of these side effects causes you problems, talk to your doctor.<br />Side effects reported since the launch of CoAprovel<br />Some undesirable effects have been reported since marketing of CoAprovel. Undesirable effects where the frequency is not known are: headache, ringing in the ears, cough, taste disturbance, indigestion, pain in joints and muscles, liver function abnormal and impaired kidney function, increased level of potassium in your blood and allergic reactions such as rash, hives, swelling of the face, lips, mouth, tongue or throat. Uncommon cases of jaundice (yellowing of the skin and/or whites of the eyes) have also been reported.<br />As for any combination of two active substances, side effects associated with each individual component cannot be excluded.<br />Side effects associated with irbesartan alone<br />In addition to the side effects listed above, chest pain, severe allergic reactions (anaphylactic shock), and decrease in the number of platelets (a blood cell essential for the clotting of the blood) have also been reported.<br />Side effects associated with hydrochlorothiazide alone<br />Loss of appetite; stomach irritation; stomach cramps; constipation; jaundice (yellowing of the skin and/or whites of the eyes); inflammation of the pancreas characterised by severe upper stomach pain, often with nausea and vomiting; sleep disorders; depression; blurred vision; lack of white blood cells, which can result in frequent infections, fever; decrease in the number of platelets (a blood cell essential for the clotting of the blood), decreased number of red blood cells (anaemia) characterised by tiredness, headaches, being short of breath when</p><p>exercising, dizziness and looking pale; kidney disease; lung problems including pneumonia or build-up of fluid in the lungs; increased sensitivity of the skin to the sun; inflammation of blood vessels; a skin disease characterized by the peeling of the skin all over the body; cutaneous lupus erythematosus, which is identified by a rash that may appear on the face, neck, and scalp; allergic reactions; weakness and muscle spasm; altered heart rate; reduced blood pressure after a change in body position; swelling of the salivary glands; high sugar levels in the blood; sugar in the urine; increases in some kinds of blood fat; high uric acid levels in the blood, which may cause gout.<br />Not known (frequency cannot be estimated from the available data): skin and lip cancer (non-melanoma skin cancer).<br />It is known that side effects associated with hydrochlorothiazide may increase with higher doses of hydrochlorothiazide.</p><p><strong>For reporting any side effects please contact KSA</strong><br />The National Pharmacovigilance and Drug Safety<br />Center (NPC)<br />&bull; Fax: +966-11-205-7662<br />&bull; Call NPC at +966-11-2038222, Exts: 2317-2356<br />2353- 2354-2334-2340<br />Toll free phone: 8002490000<br />&bull; Email: npc.drug@sfda.gov.sa<br />&bull; Website: www.sfda.gov.sa/npc<br />Sanofi - Pharmacovigilance:<br />KSA_Pharmacovigilance@sanofi.com</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />Do not use this medicine after the expiry date which is stated on the carton and on the blister after EXP. The expiry date refers to the last day of that month.<br />Do not store above 30&deg;C.<br />Store in the original package in order to protect from moisture.<br />Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><br />▪ The active substances are irbesartan and hydrochlorothiazide. Each film-coated tablet of CoAprovel 300 mg/12.5 mg contains 300 mg irbesartan and 12.5 mg hydrochlorothiazide.<br />▪ The other ingredients are lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, hypromellose, silicon dioxide, magnesium stearate, titanium dioxide, macrogol 3000, red and yellow ferric oxides, carnauba wax. Please see section 2 &ldquo;CoAprovel contains lactose&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                CoAprovel 300 mg/12.5 mg film-coated tablets are peach, biconvex, oval-shaped, with a heart debossed on one side and the number 2876 engraved on the other side.
CoAprovel 300 mg/12.5 mg film-coated tablets are supplied in blister packs of 14, 28, 30, 56, 84, 90 or 98 film-coated tablets. Unit dose blister packs of 56 x 1 film-coated tablet for delivery in hospitals are also available.
Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong><br />Sanofi Clir SNC<br />54, rue La Bo&eacute;tie<br />F-75008 Paris - France<br /><strong>Manufacturer</strong><br />SANOFI WINTHROP INDUSTRIE<br />1, rue de la Vierge<br />Ambar&egrave;s &amp; Lagrave<br />F-33565 Carbon Blanc Cedex &ndash; France<br /><strong>Secondary Packaging</strong><br />Sanofi-Aventis Arabia Co.Ltd, Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                December 2018
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>كوأبروفيل هو مزيج من مادتين فاعلتين، الإربيزارتان والهيدروكلوروثيازيد.<br />ينتمي الإربيزارتان إلى مجموعة من الأدوية تُعرف بمضادات مستقبلات الأنجيوتنسين- II . الأنجيوتنسين- II مادة تُن ت ج في<br />الجسم وترتبط بمستقبلات في الأوعية الدمويّة مما يسبّب تضيّقها ويؤدّي إلى ارتفاع في ضغط الدم. يمنع الإربيزارتان<br />ارتباط الأنجيوتنسين- II بهذه المستقبلات فتسترخي بالتالي الأوعية الدمويّة وينخفض ضغط الدم.<br />ينتمي الهيدروكلوروثيازيد إلى مجموعة أدوية )تُسمّى مدرّات البول من الثيازيد( تزيد من إخراج البول وبالتالي تخفّض<br />ضغط الدم .<br />تعمل المادتان الفاعلتان في كوأبروفيل معا لتخفيض ضغط الدم أكثر مما لو كانت كلّ مادة تُعطى لوحدها.<br /><strong>يُستعمل كوأبرو فيل لعلاج فرط ضغط الدم المرتفع </strong>عندما لم يُعطِ العلاج بالإربيزارتان أو بالهيدروكلوروثيازيد كلّ لوحده<br />تحكّما مناسبا لضغط الدم لديك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><u><strong>موانع الاستعمال:</strong></u><br /><strong>لا تستعمل كوأبروفيل</strong><br />▪ إذا كنت تعاني من حساسيّة ضدّ الإربيزارتان أو ضدّ أيّ مركّب آخر من مركّبات هذا الدواء )المذكورة في القسم<br />6 )<br />▪ إذا كنت تعاني من حساسيّة ضدّ الهيدروكلورثيازيد أو ضدّ أيّ دواء آخر مشتقّ من السلفونامايد<br />▪ إذا كنتِ حاملا ا لأكثر من 3 أشهر )يُفضّل كذلك تفادي أخذ كوأبروفيل في مراحل الحمل الأولى الرجاء مراجعة &ndash;<br />فقرة الحمل(<br />▪ إذا كنت تعاني من مشاكل حادة في الكبد أو الكلى<br />▪ إذا كنت تعاني من صعوبة في التبوّل<br />▪ إذا وجد طبيبك أنّ لديك معدّلات مرتفعة دائما من الكالسيوم أو معدّلات منخفضة دائمًا من البوتاسيوم في الد م</p><p>إذا كنت تعاني من داء السكري أو من فشل كلويّ وكنت تُعالج بدواء يحتوي على الأليسكيرين لتخفيض ضغط<br />دمك.<br /><u><strong>احتياطات الاستعمال؛ تحذيرات خاصة:</strong></u><br /><strong>تحذيرات واحتياطات</strong><br />تحدّث إلى طبيبك قبل أن تأخذ كوأبروفيل وإذا كانت إحدى الحالات التالية تنطبق عليك:<br />▪ إذا كنت تعاني من تقيّؤ أو من إسهال حاد<br />▪ إذا كنت تعاني من مشاكل في الكلى بما في ذلك الغرس الكلوي<br />▪ إذا كنت تعاني من مشاكل في القلب<br />▪ إذا كنت تعاني من مشاكل في الكبد<br />▪ إذا كنت تعاني من داء السكّري<br />▪ إذا كنت تعاني من الذأب الحمامي )المعروف أيضا بالذأب أو بالذأب الحمامي المجموعي(<br />▪ إذا كنت تعاني من فرط إنتاج الألدوستيرون الأوّلي )حالة متصلة بالإنتاج العالي لهورمون الألودستيرون مما<br />يسبّب احتباس الصوديوم وبالتالي ارتفاعًا في ضغط الدم(.<br />▪ إذا كنت تأخذ أحد الأدوية التالية لعلاج فرط ضغط الدم:<br />- &quot;مثبّط انزيم تحويل الأنجيوتنسين&quot; )مثلاً إينالابريل، ليزينوبريل، راميبريل(، بخاصة إذا كنت تعاني من<br />مشاكل كلويّة ناتجة عن داء السكّري.<br />- الأليسكيرين.<br />▪ إذا كنت مصابًا بسرطان في الجلد أو إذا أصبت بآفة جلديّة غير متوقّعة في خلال العلاج. إنّ العلاج<br />بالهيدروكلورثيازيد، بخاصة عند استعماله لفترة طويلة وبجرعات عالية، يمكن أن يزيد خطر الإصابة ببعض<br />أنواع سرطان الجلد والشفتين )سرطان الجلد غير القتامي(. إحمِ بشرتك من أشعّة الشمس ومن الأشعة فوق<br />البنفسجيّة عندما تأخذ كوأبروفيل.<br />قد يراقب طبيبك بانتظام وظيفتك الكلويّة وضغط الدم لديك ومعدّلات المنحلاّت الكهرباويّة )البوتاسيوم مثلاً( في دمك.<br />راجع أيضًا المعلومات الواردة في فقرة &quot;لا تستعمل كوأبروفيل&quot;.<br />يجب عليكِ أن تُعلمي طبيبك إذا كنتِ تعتقدين أنّكِ حامل )أو أنكِ قد تُصبحين حاملا (. لا يوصى باستعمال كوأبروفيل في<br />المرحلة الأولى من الحمل ولا ينبغي أخذه إذا كنتِ حاملاً لأكثر من 3 أشهر فقد يسبّب مشاكل صحيّة خطيرة لطفلك إذا<br />استُعمل في هذه المرحلة )راجع فقرة الحمل(.<br /><strong>يجب عليك أيضاا إعلام الطبيب:</strong><br />▪ إذا كنت تتبع حمية قليلة الملح<br />▪ إذا كنت تعاني من عوارض معيّنة كالظمأ غير الطبيعي وجفاف الفم والضعف العام والنعاس وألم العضلات أو<br />المعص العضلي والغثيان والتقيّؤ أو دقّة قلب سريعة بشكل غير طبيعي مما قد يدلّ على مفعول مفرط<br />للهيدروكلوروثيازيد )الذي يحتوي كوأبروفيل عليه(<br />▪ إذا تعرّ ضت لزيادة في حساسيّة الجلد تجاه الشمس مع عوارض حرق الشمس )كالاحمرار والحكاك والتورّم<br />والتنفّط( التي تحصل أسرع من العادة<br />▪ إذا كنت ستخضع لأيّ عمليّة جراحيّة أو كنت ستتلقّى مواداا مخدّرة<br />▪ إذا واجهت تغييرات في نظرك أو أل ا ما في إحدى عينيك أو في كليهما في خلال العلاج بكوأبروفيل. فقد يكون هذا<br />إشارة على أنّك تُصاب بالغلوكوما أي بزيادة الضغط في عينك أو عينيك. يجب عليك إيقاف العلاج بكوأبروفيل<br />واستشارة الطبيب.<br />إن الهيدروكلوروثيازيد الذي يحتويه هذا الدواء يمكن أن يعط ي نتيجة إيجابيّة في الفحص الكاشف لتعاطي المنشّطات.<br /><strong>الأطفال والمراهقون</strong><br />لا ينبغي إعطاء كوأبروفيل للأطفال والمراهقين )ما دون 18 عامًا(.<br /><strong>أدوية أخرى وكوأبروفيل</strong><br />الرجاء إعلام الطبيب أو الصيدلي إذا كنت تتناول حاليّا أو تناولت مؤخّراً أو قد تتناول أيّ دواء آخر.</p><p>إنّ مدرّات البول مثل الهيدروكلوروثيازيد الذي يحتوي كوأبروفيل عليه قد يكون لها مفعول على أدوية أخرى. يجب عدم<br />تناول الأدوية التي تحتوي على الليثيوم مع كوأبروفيل بدون مراقبة دقيقة من طبيبك.<br />قد يُضطرّ طبيبك إلى تغيير جرعتك و/أو اتخاذ احتياطات أخرى:<br />إذا كنت تأخذ مثبّطً ا لانزيم تحويل الأنجيوتنسين أو الأليسكيرين )راجع أيضًا المعلومات الواردة في فقرتيّ &quot;لا تستعمل<br />كوأبروفيل&quot; و&quot;تحذيرات واحتياطات&quot;(.<br /><strong>قد تحتاج إلى إجراء فحوصات دم إذا كنت تتناول:</strong><br />▪ مكمّلات البوتاسيوم،<br />▪ بدائل الملح التي تحتوي على البوتاسيوم،<br />▪ الأدوية التي تحافظ على البوتاسيوم أو مدرّات بول أخرى،<br />▪ بعض المليّنات،<br />▪ أدوية لعلاج النّقرس،<br />▪ مكمّلات الفيتامين د العلاجيّة،<br />▪ أدوية التحكّم بنظم القلب،<br />▪ أدوية داء السكّري )الأدوية الفمويّة أو الأنسولين(،<br />▪ الكاربامازيبين )دواء لعلاج الصرع(.<br />من المهمّ أيضا أن تُعلم طبيبك في حال كنت تتناول أدوية أخرى لتخفيض ضغط الدم أو ستيرويدات أو أدوية لعلاج<br />السرطان أو مسكّنات أو أدوية لعلاج التهاب المفاصل أو راتنجات الكولسترامين والكوليستيبول لتخفيض كولسترول الدم.<br /><strong>أخذ كوأبروفيل مع الطعام والشراب</strong><br />يمكن أخذ كوأبروفيل مع الطعام أو بدونه.<br />بسبب احتواء كوأبروفيل على الهيدروكلوروثيازيد، إذا تناولت الكحول في خلال فترة العلاج بهذا الدواء قد يزداد شعورك<br />بالدوار عند الوقوف بخاصة عند النهوض بعد الجلوس.<br /><strong>الحمل والإرضاع والخصوبة</strong><br /><strong>الحمل</strong><br />يجب أن تُعلمي طبيبك إذا كنتِ تعتقدين أنّكِ حامل )أو أنكِ قد تُصبحين حاملا (. سوف يطلب منك طبيبك عادة التوقّف عن<br />أخذ كوأبروفيل قبل أن تحملي أو حالما تعرفين أنّكِ حامل وسوف يصف لكِ أخذ دواء غير كوأبروفيل لأنّ كوأبروفيل لا<br />يُنصح به في بداية فترة الحمل ولا ينبغي أخذه بعد 3 أشهر من الحمل فقد يسبّب مشاكل صحيّة خطيرة لطفلك إذا استُعمل<br />ابتداء من الشهر الثالث من الحمل.<br /><strong>الإرضاع</strong><br />أعلمي طبيبك إذا كنتِ تُرضِعين أو كنت على وشك الإرضاع. لا يوصى باستعمال كوأبروفيل لدى الأمّهات المرضعات<br />ويمكن أن يختار لكِ طبيبكِ علاجًا آخر إذا كنتِ ترغبين بالإرضاع بخاصة إذا كان طفلكِ حديث الولادة أو وُلد قبل أوانه.<br /><strong>قيادة السيّارات واستعمال الآلات</strong><br />من غير المحتمل أن يؤثّر كوأبروفيل على قدرتك على قيادة السيّارات أو على استعمال الآلات. ولكن قد تُصاب أحيانا بالدوار أو بالتعب أثناء علاج فرط ضغط الدم. في هذه الحالة يجب عليك إعلام الطبيب.<br /><strong>يحتوي كوأبروفيل على اللاكتوز.</strong> إذا قال لك الطبيب إنّك تعاني من عدم تحمّل بعض أنواع السكّر )اللاكتوز مثلا (، اتصل<br />به قبل أخذ هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>إحرص على أخذ هذا الدواء دائما وفقا لتعليمات الطبيب أو الصيدلي. يجب عليك التحقّق من الطبيب أو من الصيدلي إذا لم<br />تكن متأكّداً.</p><p style="text-indent:50px"><strong>مقدار الجرعة</strong><br />تبلغ الجرعة العاديّة من كوأبروفيل قرصا واحداً في اليوم. عادة ما يصف لك طبيبك كوأبروفيل عندما لم يُعطِ علاجك<br />السابق لارتفاع ضغط الدم أيّ انخفاض مناسب في ضغط الدم. سوف يعلمك طبيبك كيف تنتقل من العلاج السابق إلى<br />كوأبروفيل.<br /><strong>طريقة أخذ الدواء</strong><br />كوأبروفيل هو للاستعمال عن طريق الفم. يجب بلع الأقراص مع كميّة كافية من السوائل )مثلاً كوب ماء(. يمكنك أخذ<br />كوأبروفيل مع الطعام أو بدون الطعام. حاول أخذ جرعتك اليوميّة في الوقت نفسه تقريبًا كلّ يوم. من المهمّ أن تواصل أخذ<br />كوأبروفيل إلى أن يأمرك الطبيب بالتوقّف عن أخذه .<br />يجب بلوغ المفعول الأقصى المخفّض لضغط الدم بعد فترة تتراوح بين 6 و 8 أسابيع من بداية العلاج.<br /><strong>إذا أخذت كميّة كوأبروفيل أكثر من التي عليك أخذها</strong><br />إذا أخذت عن طريق الخطأ عدداً من الأقراص أكثر مما يجب، اتّصل بالطبيب على الفور.<br /><strong>لا ينبغي بالأطفال أخذ كوأبروفيل</strong><br />لا ينبغي إعطاء كوأبروفيل للأطفال ما دون ال 18 من العمر. في حال بلع طفل بعض الأقراص، اتّصل بالطبيب على الفور.<br /><strong>إذا نسيت أخذ كوأبروفيل</strong><br />إذا فوّت جرعة يوميّة عن طريق الخطأ، تناول الجرعة التالية كالمعتاد. لا تأخذ جرعة مضاعفة للتعويض عن الجرعة التي<br />فوّتها.<br />إذا كان لديك أيّ أسئلة إضافيّة حول استعمال هذا الدواء، إسأل الطبيب أو الصيدلي للحصول على المزيد من المعلومات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل الأدوية كلّها، يمكن أن يسبّب هذا الدواء تأثيرات جانبيّة لا تصيب المرضى كلّهم. يمكن أن يكون بعض هذه التأثيرات<br />الجانبيّة خطيراً وقد يتط لّب عناية طبيّة.<br />أفيد عن حالات نادرة من الارتكاسات الجلديّة التحسسيّة )طفح، شرى(، ومن التورّم الموضعيّ للوجه و/أو الشفتين و/أو<br />اللسان لدى مرضى يتناولون الإربيزارتان.<br /><strong>في حال أصبت بأحد هذه العوارض أو بضيق نفس</strong>، توقّف عن أخذ كوأبروفيل واتصل بالطبيب على الفور.<br />يُحدّد معدّل الإصابة بالتأثيرات الجانبيّة المذكورة أدناه وفقا لما يلي:<br />الشائعة: قد تصيب حتّى مريض واحد من أصل 10 مرض ى<br />غير الشائعة: قد تصيب حتّى مريض واحد من أصل 100 مريض<br />كانت التأثيرات الجانبيّة التي أفيد عنها في الدراسات السريريّة لدى المرضى المُعالجين بكوأبروفيل:<br />التأثيرات الجانبيّة الشائعة )قد تصيب حتّى مريض واحد من أصل 10 مرضى(<br />▪ غثيان/تقيّؤ<br />▪ حاجة غير طبيعيّة للتبوّل<br />▪ تعب<br />▪ دوار )بما في ذلك عند النهوض بعد الاستلقاء أو الجلوس(<br />▪ فحوصات دم يمكن أن تُظهر ارتفاعا في مستويات إنزيم يقيس وظيفة العضلات والقلب )كيناز الكرياتين( أو<br />مستويات مرتفعة من مواد تقيس وظيفة الكلى )نتروجين بولة الدم، الكرياتينين(.<br />إذا سبّب لك أحد التأثيرات الجانبيّة هذه أيّ إزعاج، تحدّث إلى طبيبك.<br /><strong>التأثيرات الجانبيّة غير الشائعة</strong> (قد تصيب حتّى مريض واحد من أصل 100 مريض):<br />▪ إسهال<br />▪ انخفاض ضغط الد م</p><p>▪ ضعف<br />▪ زيادة سرعة القل ب<br />▪ هبّات ساخنة<br />▪ أوديما<br />▪ عسر الوظيفة الجنسيّة )مشاكل في الأداء الجنسيّ(<br />▪ يمكن أن تُظهر فحوصات الدم معدّلات منخفضة من البوتاسيوم والصوديوم في الدم.<br /><strong>إذا سبّب لك أحد التأثيرات الجانبيّة أيّ إزعاج، تحدّث إلى طبيبك.</strong></p><p><br /><strong>التأثيرات الجانبيّة التي أُفيد عنها منذ تسويق كوأبروفيل</strong><br />منذ تسويق كوأبروفيل، أفيد عن بعض التأثيرات غير المرغوب بها. التأثيرات غير المرغوب بها التي لا يُعرف معدّل<br />الإصابة بها هي: صداع، طنين في الأذنين، سعال، اضطراب في الذوق، عسر هضم، ألم في المفاصل والعضلات، وظيفة<br />غير طبيعيّة للكبد وضعف في الوظيفة الكلويّة، زيادة معدّل البوتاسيوم في الدم وارتكاسات تحسسيّة مثل الطفح والشرى<br />وتورّم الوجه أو الشفتين أو الفم أو اللسان أو الحلق. كما أفيد عن حالات غير شائعة من اليرقان )اصفرار البشرة و/أو<br />بياض العينين(.<br />كما بالنسبة إلى أيّ مزيج لمادتين فاعلتين، لا يمكن استثناء التأثيرات الجانبيّة الناتجة عن كلّ مركّب فرديّ .<br /><strong>التأثيرات الجانبيّة المتعلّقة بالإربيزارتان لوحده</strong><br />بالإضافة إلى التأثيرات الجانبيّة المذكورة أعلاه، أفيد أيضًا عن أوجاع في الصدر، وعن ارتكاسات تحسسيّة حادة )صدمة<br />عورانيّة( وعن انخفاض عدد الصفيحات )مركّب دمويّ أساسيّ يسمح بتخثّر الدم(.<br /><strong>التأثيرات الجانبيّة الناتجة عن الهيدروكلوروثيازيد لوحده</strong><br />فقدان الشهيّة، تهيّج المعدة، معص المعدة، إمساك، يرقان )اصفرار البشرة و/أو بياض العينين(، التهاب البنكرياس المتميّز<br />بألم حاد في أعلى المعدة غالبا ما يترافق مع غثيان وتقيّؤ، اضطرابات في النوم، اكتئاب، عدم وضوح في الرؤية، نقص<br />كريات الدم البيضاء مما قد يسبّب حالات عدوى متكررة، حمى، انخفاض عدد الصفيحات الدمويّة )مركّب دمويّ أساسيّ<br />يسمح بتخثّر الدم(، انخفاض عدد كريات الدم الحمر )فقر دم( يتميّز بالتعب والصداع وضيق النفس عند ممارسة الرياضة،<br />دوار وشحوب، مرض كلويّ، مشاكل في الرئتين تتضمّن ذات الرئة أو تراكم السوائل في الرئتين، زيادة الحساسيّة الجلديّة<br />تجاه الشمس، التهاب الأوعية الدمويّة، مرض جلدي يتميّز بتقشّر الجلد في الجسم كلّه، ذأب حمامي جلدي يتمّ التعرّف إليه<br />من خلال طفح قد يظهر على الوجه والعنق وفروة الرأس، ارتكاسات تحسسيّة، ضعف وتشنّج عضلي، تغيير في النبض،<br />انخفاض في ضغط الدم بعد تغيير وضعيّة الجسم، تورّم الغدد اللعابيّة، ارتفاع معدّلات السكر في الدم، سكّر في البول،<br />زيادات في بعض أنواع شحم الدم، ارتفاع في معدّلات حمض البوليك في الدم مما قد يسبّب النّقرس.<br /><strong>التأثيرات غير المعروفة معدّل الحصول</strong> (لا يمكن تقدير معدّل حصولها استنادًا إلى البيانات المتاحة(: سرطان الجلد<br />والشفتين )سرطان الجلد غير القتامي).<br />من المعروف أنّ التأثيرات الجانبيّة الناتجة عن الهيدروكلوروثيازيد قد تزيد مع الجرعات الأعلى من الهيدروكلوروثيازيد.<br /><strong>الإفادة عن التأثيرات الجانبيّة</strong><br />إذا أصبت بأيّ تأثيرات جانبيّة أعلم الطبيب أو الصيدلي. ويتضمّن هذا أيّ تأثيرات جانبيّة غير مذكورة في هذه النشرة.<br />بالإفادة عن التأثيرات الجانبيّة يمكنك المساعدة على تزويد المزيد المعلومات حول سلامة هذا الدواء.<br /><strong>للإبلاغ عن أي أع ا رض جانبية :<br />&bull; المملكة العربية السعودية :</strong></p><p>المركز الوطني للتيقظ والسلامة الدوائية<br />o فاكس: ٧٦٦٢ - ٢٠٥ - ١١ - ٩٦٦ +<br />o للاتصال بالإدارة التنفيذية للتّيقّظ وإدارة الأزما ت:<br />o هاتف: ٨٢٢٢ - ٢٠٣ - ١١ - ٩٦٦ +<br />تحويلة: ٢٣١٧ &ndash; 2356 - 2340<br />o الرقم المُوحّ د للهيئة العامّة للغذاء والدّواء: 19999<br />o البري د الإلكتروني: npc.drug@sfda.gov.sa<br />o الموقع الإلكتروني: www.sfda.gov.sa/npc<br /><strong>سانوفي للتيقظ الدوائ ي</strong> KSA_Pharmacovigilance@sanofi.co</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>إحفظ الدواء بعيداً عن نظر الأطفال ومتناولهم.<br />لا تستعمل هذا الدواء بعد انقضاء تاريخ الصلاحيّة المدوّن على العلبة الخارجيّة وعلى الظرف المشكّل حراريًا. يشير تاريخ<br />انقضاء الصلاحيّة إلى اليوم الأخير من الشهر المذكور.<br />يُحفظ في درجة حرارة لا تتجاوز 30 درجة مئويّة.<br />يُحفظ في علبته الخارجيّة الأصليّة بعيداً عن الرطوبة.<br />لا ينبغي التخلّص من الأدوية في مياه الصرف الصحّي أو النفايات المنزليّة. اطلب من الصيدليّ التخلّص من الأدوية التي لم<br />تعد تستعملها. فمن شأن هذه الإجراءات حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>▪ المادتان الفاعلتان هما الإربيزارتان والهيدروكلوروثيازيد. يحتوي كلّ قرص مغلّف من كوأبروفيل 300<br />ملغ/ 12.5 ملغ على 300 ملغ من الإربيزارتان وعلى 12.5 ملغ من الهيدروكلوروثيازيد.<br />▪ المركّبات الأخرى هي: لاكتوز وحيد التميّه، سلولوز دقيق البلّوريّة، كروسكارميلوز الصوديوم، هبروميلوز، ثاني<br />أكسيد السيليكون، ستيارات المغنيزيوم، ثاني أكسيد التيتانيوم، ماكروغول 3000 ، أكسيد الحديد الأحمر والأصفر،<br />شمع كوبرنيكيّ. راجع فقرة &quot;يحتوي كوأبروفيل على اللاكتوز&quot;.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right">أقراص كوأبروفيل 300 ملغ/ 12.5 ملغ المغلّفة هي أقراص قرنفليّة اللون، ثنائيّة التحدّب وبيضاويّة الشكل مع قلب محفور<br />على جهة واحدة والرقم 2876 على الجهة الأخرى .<br />يأتي كوأبروفيل 300 ملغ/ 12.5 ملغ أقراص مغلّفة، في علب ظروف من 14 أو 28 أو 30 أو 56 أو 84 أو 90 أو 98<br />قرصا مغلّف ا في ظروف مشكّلة حراريًا. كما تتوافر علب ظروف أحاديّة الجرعة من 56x1 قرص مغلّف للاستعمال في<br />المستشفيات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>حامل رخصة التسويق</strong><br />Sanofi Clir SNC<br />54, rue La Bo&eacute;tie<br />F-75008 Paris &ndash; France<br /><strong>المصنّع</strong><br />SANOFI WINTHROP INDUSTRIE<br />1, rue de la Vierge<br />Ambar&egrave;s &amp; Lagrave<br />F-33565 Carbon Blanc Cedex &ndash; France<br /><strong>التغليف الثانوي</strong><br />Sanofi-Aventis Arabia Co. Ltd,<br />Saudi Arabia</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            Dec/2018
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                CoAprovel 300 mg/12.5 mg tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains 300 mg of irbesartan and 12.5 mg of hydrochlorothiazide.
Excipient with known effect:
Each tablet contains 65.8 mg of lactose (as lactose monohydrate).
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablet.
Peach, biconvex, oval-shaped, with a heart debossed on one side and the number 2776 engraved on the
other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of essential hypertension.<br />This fixed dose combination is indicated in adult patients whose blood pressure is not adequately<br />controlled on irbesartan or hydrochlorothiazide alone (see section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u><br />CoAprovel can be taken once daily, with or without food.<br />Dose titration with the individual components (i.e. irbesartan and hydrochlorothiazide) may be<br />recommended.<br />When clinically appropriate direct change from monotherapy to the fixed combinations may be<br />considered:<br /> CoAprovel 150 mg/12.5 mg may be administered in patients whose blood pressure is not<br />adequately controlled with hydrochlorothiazide or irbesartan 150 mg alone;<br /> CoAprovel 300 mg/12.5 mg may be administered in patients insufficiently controlled by<br />irbesartan 300 mg or by CoAprovel 150 mg/12.5 mg.<br /> CoAprovel 300 mg/25 mg may be administered in patients insufficiently controlled by<br />CoAprovel 300 mg/12.5 mg.<br />Doses higher than 300 mg irbesartan/25 mg hydrochlorothiazide once daily are not recommended.<br />When necessary, CoAprovel may be administered with another antihypertensive medicinal product<br />(see sections 4.3, 4.4, 4.5 and 5.1).</p><p><u>Special Populations</u><br />Renal impairment<br />Due to the hydrochlorothiazide component, CoAprovel is not recommended for patients with severe<br />renal dysfunction (creatinine clearance &lt; 30 ml/min). Loop diuretics are preferred to thiazides in this<br />population. No dosage adjustment is necessary in patients with renal impairment whose renal<br />creatinine clearance is &ge; 30 ml/min (see sections 4.3 and 4.4).<br />Hepatic impairment<br />CoAprovel is not indicated in patients with severe hepatic impairment. Thiazides should be used with<br />caution in patients with impaired hepatic function. No dosage adjustment of CoAprovel is necessary in<br />patients with mild to moderate hepatic impairment (see section 4.3).<br />Older people<br />No dosage adjustment of CoAprovel is necessary in older people.<br />Paediatric population<br />CoAprovel is not recommended for use in children and adolescents because the safety and efficacy<br />have not been established. No data are available.<br /><u>Method of Administration</u><br />For oral use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 Hypersensitivity to the active substances or to any of the excipients listed in section 6.1, or to
other sulfonamide-derived substances (hydrochlorothiazide is a sulfonamide-derived substance)
 Second and third trimesters of pregnancy (see sections 4.4 and 4.6)
 Severe renal impairment (creatinine clearance < 30 ml/min)
 Refractory hypokalaemia, hypercalcaemia
 Severe hepatic impairment, biliary cirrhosis and cholestasis
 The concomitant use of CoAprovel with aliskiren-containing products is contraindicated in
patients with diabetes mellitus or renal impairment (glomerular filtration rate (GFR)
<60 ml/min/1.73 m²) (see sections 4.5 and 5.1).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Hypotension - Volume-depleted patients:</u> CoAprovel has been rarely associated with symptomatic<br />hypotension in hypertensive patients without other risk factors for hypotension. Symptomatic<br />hypotension may be expected to occur in patients who are volume and/or sodium depleted by vigorous<br />diuretic therapy, dietary salt restriction, diarrhoea or vomiting. Such conditions should be corrected<br />before initiating therapy with CoAprovel.<br /><u>Renal artery stenosis - Renovascular hypertension:</u> there is an increased risk of severe hypotension and<br />renal insufficiency when patients with bilateral renal artery stenosis or stenosis of the artery to a single<br />functioning kidney are treated with angiotensin converting enzyme inhibitors or angiotensin-II<br />receptor antagonists. While this is not documented with CoAprovel, a similar effect should be<br />anticipated.<br /><u>Renal impairment and kidney transplantation: </u>when CoAprovel is used in patients with impaired renal<br />function, a periodic monitoring of potassium, creatinine and uric acid serum levels is recommended.<br />There is no experience regarding the administration of CoAprovel in patients with a recent kidney</p><p>transplantation. CoAprovel should not be used in patients with severe renal impairment (creatinine<br />clearance &lt; 30 ml/min) (see section 4.3). Thiazide diuretic-associated azotaemia may occur in patients<br />with impaired renal function. No dosage adjustment is necessary in patients with renal impairment<br />whose creatinine clearance is &ge; 30 ml/min. However, in patients with mild to moderate renal<br />impairment (creatinine clearance &ge; 30 ml/min but &lt; 60 ml/min) this fixed dose combination should be<br />administered with caution.<br /><u>Dual blockade of the renin-angiotensin-aldosterone system (RAAS):</u> there is evidence that the<br />concomitant use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren increases the risk of<br />hypotension, hyperkalaemia and decreased renal function (including acute renal failure). Dual<br />blockade of RAAS through the combined use of ACE-inhibitors, angiotensin II receptor blockers or<br />aliskiren is therefore not recommended (see sections 4.5 and 5.1). If dual blockade therapy is<br />considered absolutely necessary, this should only occur under specialist supervision and subject to<br />frequent close monitoring of renal function, electrolytes and blood pressure. ACE-inhibitors and<br />angiotensin II receptor blockers should not be used concomitantly in patients with diabetic<br />nephropathy.<br /><u>Hepatic impairment:</u> thiazides should be used with caution in patients with impaired hepatic function<br />or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate<br />hepatic coma. There is no clinical experience with CoAprovel in patients with hepatic impairment.<br />Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy: as with other vasodilators,<br />special caution is indicated in patients suffering from aortic or mitral stenosis, or obstructive<br />hypertrophic cardiomyopathy.<br /><u>Primary aldosteronism:</u> patients with primary aldosteronism generally will not respond to<br />antihypertensive medicinal products acting through inhibition of the renin-angiotensin system.<br />Therefore, the use of CoAprovel is not recommended.</p><p><u>Metabolic and endocrine effects:</u> thiazide therapy may impair glucose tolerance. In diabetic patients<br />dosage adjustments of insulin or oral hypoglycemic agents may be required. Latent diabetes mellitus<br />may become manifest during thiazide therapy.<br />Increases in cholesterol and triglyceride levels have been associated with thiazide diuretic therapy;<br />however at the 12.5 mg dose contained in CoAprovel, minimal or no effects were reported.<br />Hyperuricaemia may occur or frank gout may be precipitated in certain patients receiving thiazide<br />therapy.<br /><u>Electrolyte imbalance:</u> as for any patient receiving diuretic therapy, periodic determination of serum<br />electrolytes should be performed at appropriate intervals.<br />Thiazides, including hydrochlorothiazide, can cause fluid or electrolyte imbalance (hypokalaemia,<br />hyponatraemia, and hypochloremic alkalosis). Warning signs of fluid or electrolyte imbalance are<br />dryness of mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pain or cramps,<br />muscular fatigue, hypotension, oliguria, tachycardia, and gastrointestinal disturbances such as nausea<br />or vomiting.<br />Although hypokalaemia may develop with the use of thiazide diuretics, concurrent therapy with<br />irbesartan may reduce diuretic-induced hypokalaemia. The risk of hypokalaemia is greatest in patients<br />with cirrhosis of the liver, in patients experiencing brisk diuresis, in patients who are receiving<br />inadequate oral intake of electrolytes and in patients receiving concomitant therapy with<br />corticosteroids or ACTH. Conversely, due to the irbesartan component of CoAprovel hyperkalaemia<br />might occur, especially in the presence of renal impairment and/or heart failure, and diabetes mellitus.<br />Adequate monitoring of serum potassium in patients at risk is recommended. Potassium-sparing<br />diuretics, potassium supplements or potassium-containing salts substitutes should be co-administered<br />cautiously with CoAprovel (see section 4.5).</p><p>There is no evidence that irbesartan would reduce or prevent diuretic-induced hyponatraemia. Chloride<br />deficit is generally mild and usually does not require treatment.<br />Thiazides may decrease urinary calcium excretion and cause an intermittent and slight elevation of<br />serum calcium in the absence of known disorders of calcium metabolism. Marked hypercalcaemia<br />may be evidence of hidden hyperparathyroidism. Thiazides should be discontinued before carrying out<br />tests for parathyroid function.<br />Thiazides have been shown to increase the urinary excretion of magnesium, which may result in<br />hypomagnaesemia.<br />Lithium: the combination of lithium and CoAprovel is not recommended (see section 4.5).<br />Anti-doping test: hydrochlorothiazide contained in this medicinal product could produce a positive<br />analytic result in an anti-doping test.<br /><u>General</u>: in patients whose vascular tone and renal function depend predominantly on the activity of<br />the renin-angiotensin-aldosterone system (e.g. patients with severe congestive heart failure or<br />underlying renal disease, including renal artery stenosis), treatment with angiotensin converting<br />enzyme inhibitors or angiotensin-II receptor antagonists that affect this system has been associated<br />with acute hypotension, azotaemia, oliguria, or rarely acute renal failure (see section 4.5). As with any<br />antihypertensive agent, excessive blood pressure decrease in patients with ischemic cardiopathy or<br />ischemic cardiovascular disease could result in a myocardial infarction or stroke.<br />Hypersensitivity reactions to hydrochlorothiazide may occur in patients with or without a history of<br />allergy or bronchial asthma, but are more likely in patients with such a history.<br />Exacerbation or activation of systemic lupus erythematosus has been reported with the use of thiazide<br />diuretics.<br />Cases of photosensitivity reactions have been reported with thiazides diuretics (see section 4.8). If<br />photosensitivity reaction occurs during treatment, it is recommended to stop the treatment. If a readministration<br />of the diuretic is deemed necessary, it is recommended to protect exposed areas to the<br />sun or to artificial UVA.<br /><strong><u>Pregnancy:</u></strong> angiotensin II Receptor Antagonists (AIIRAs) should not be initiated during pregnancy.<br />Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be<br />changed to alternative antihypertensive treatments which have an established safety profile for use in<br />pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately,<br />and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6).<br />Acute Myopia and Secondary Acute Angle-Closure Glaucoma: sulfonamide drugs or sulfonamide<br />derivative drugs can cause an idiosyncratic reaction, resulting in transient myopia and acute angleclosure<br />glaucoma. While hydrochlorothiazide is a sulfonamide, only isolated cases of acute angleclosure<br />glaucoma have been reported so far with hydrochlorothiazide. Symptoms include acute onset<br />of decreased visual acuity or ocular pain and typically occur within hours to weeks of drug initiation.<br />Untreated acute angle-closure glaucoma can lead to permanent vision loss. The primary treatment is to<br />discontinue drug intake as rapidly as possible. Prompt medical or surgical treatments may need to be<br />considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angleclosure<br />glaucoma may include a history of sulfonamide or penicillin allergy (see section 4.8).<br /><u>Lactose: </u>Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or<br />glucose-galactose malabsorption should not take this medicine.<br /><u>Non-melanoma skin cancer</u></p><p>An increased risk of non-melanoma skin cancer (NMSC) [basal cell carcinoma (BCC) and squamous<br />cell carcinoma (SCC)] with increasing cumulative dose of hydrochlorothiazide (HCTZ) exposure has<br />been observed in two epidemiological studies based on the Danish National Cancer Registry.<br />Photosensitizing actions of HCTZ could act as a possible mechanism for NMSC.<br />Patients taking HCTZ should be informed of the risk of NMSC and advised to regularly check their<br />skin for any new lesions and promptly report any suspicious skin lesions. Possible preventive<br />measures such as limited exposure to sunlight and UV rays and, in case of exposure, adequate<br />protection should be advised to the patients in order to minimize the risk of skin cancer. Suspicious<br />skin lesions should be promptly examined potentially including histological examinations of biopsies.<br />The use of HCTZ may also need to be reconsidered in patients who have experienced previous NMSC<br />(see also section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Other antihypertensive agents:</u> the antihypertensive effect of CoAprovel may be increased with the<br />concomitant use of other antihypertensive agents. Irbesartan and hydrochlorothiazide (at doses up to<br />300 mg irbesartan/25 mg hydrochlorothiazide) have been safely administered with other<br />antihypertensive agents including calcium channel blockers and beta-adrenergic blockers. Prior<br />treatment with high dose diuretics may result in volume depletion and a risk of hypotension when<br />initiating therapy with irbesartan with or without thiazide diuretics unless the volume depletion is<br />corrected first (see section 4.4).<br /><u>Aliskiren-containing products or ACE-inhibitors:</u> clinical trial data has shown that dual blockade of<br />the renin-angiotensin-aldosterone system (RAAS) through the combined use of ACE-inhibitors,<br />angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events<br />such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure)<br />compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1).<br /><u>Lithium: </u>reversible increases in serum lithium concentrations and toxicity have been reported during<br />concomitant administration of lithium with angiotensin converting enzyme inhibitors. Similar effects<br />have been very rarely reported with irbesartan so far. Furthermore, renal clearance of lithium is<br />reduced by thiazides so the risk of lithium toxicity could be increased with CoAprovel. Therefore, the<br />combination of lithium and CoAprovel is not recommended (see section 4.4). If the combination<br />proves necessary, careful monitoring of serum lithium levels is recommended.<br /><u>Medicinal products affecting potassium: </u>the potassium-depleting effect of hydrochlorothiazide is<br />attenuated by the potassium-sparing effect of irbesartan. However, this effect of hydrochlorothiazide<br />on serum potassium would be expected to be potentiated by other medicinal products associated with<br />potassium loss and hypokalaemia (e.g. other kaliuretic diuretics, laxatives, amphotericin,<br />carbenoxolone, penicillin G sodium). Conversely, based on the experience with the use of other<br />medicinal products that blunt the renin-angiotensin system, concomitant use of potassium-sparing<br />diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products<br />that may increase serum potassium levels (e.g. heparin sodium) may lead to increases in serum<br />potassium. Adequate monitoring of serum potassium in patients at risk is recommended (see<br />section 4.4).</p><p><u>Medicinal products affected by serum potassium disturbances: </u>periodic monitoring of serum<br />potassium is recommended when CoAprovel is administered with medicinal products affected by<br />serum potassium disturbances (e.g. digitalis glycosides, antiarrhythmics).<br /><u>Non-steroidal anti-inflammatory drugs:</u> when angiotensin II antagonists are administered<br />simultaneously with non-steroidal anti- inflammatory drugs (i.e. selective COX-2 inhibitors,<br />acetylsalicylic acid (&gt; 3 g/day) and non-selective NSAIDs), attenuation of the antihypertensive effect<br />may occur.<br />As with ACE inhibitors, concomitant use of angiotensin II antagonists and NSAIDs may lead to an<br />increased risk of worsening of renal function, including possible acute renal failure, and an increase in</p><p>serum potassium, especially in patients with poor pre-existing renal function. The combination should<br />be administered with caution, especially in the elderly. Patients should be adequately hydrated and<br />consideration should be given to monitoring renal function after initiation of concomitant therapy, and<br />periodically thereafter.<br />Additional information on irbesartan interactions: in clinical studies, the pharmacokinetic of irbesartan<br />is not affected by hydrochlorothiazide. Irbesartan is mainly metabolised by CYP2C9 and to a lesser<br />extent by glucuronidation. No significant pharmacokinetic or pharmacodynamic interactions were<br />observed when irbesartan was coadministered with warfarin, a medicinal product metabolised by<br />CYP2C9. The effects of CYP2C9 inducers such as rifampicin on the pharmacokinetic of irbesartan<br />have not been evaluated. The pharmacokinetic of digoxin was not altered by co-administration of<br />irbesartan.<br />Additional information on hydrochlorothiazide interactions: when administered concurrently, the<br />following medicinal products may interact with thiazide diuretics:<br />Alcohol: potentiation of orthostatic hypotension may occur;<br />Antidiabetic medicinal products (oral agents and insulins): dosage adjustment of the antidiabetic<br />medicinal product may be required (see section 4.4);<br />Colestyramine and Colestipol resins: absorption of hydrochlorothiazide is impaired in the presence of<br />anionic exchange resins. CoAprovel should be taken at least one hour before or four hours after these<br />medications;<br />Corticosteroids, ACTH: electrolyte depletion, particularly hypokalaemia, may be increased;<br />Digitalis glycosides: thiazide induced hypokalaemia or hypomagnaesemia favour the onset of<br />digitalis-induced cardiac arrhythmias (see section 4.4);<br />Non-steroidal anti-inflammatory drugs: the administration of a non-steroidal anti-inflammatory drug<br />may reduce the diuretic, natriuretic and antihypertensive effects of thiazide diuretics in some patients;<br />Pressor amines (e.g. noradrenaline): the effect of pressor amines may be decreased, but not<br />sufficiently to preclude their use;<br />Nondepolarizing skeletal muscle relaxants (e.g. tubocurarine): the effect of nondepolarizing skeletal<br />muscle relaxants may be potentiated by hydrochlorothiazide;<br />Antigout medicinal products: dosage adjustments of antigout medicinal products may be necessary as<br />hydrochlorothiazide may raise the level of serum uric acid. Increase in dosage of probenecid or<br />sulfinpyrazone may be necessary. Co-administration of thiazide diuretics may increase the incidence<br />of hypersensitivity reactions to allopurinol;<br />Calcium salts: thiazide diuretics may increase serum calcium levels due to decreased excretion. If<br />calcium supplements or calcium sparing medicinal products (e.g. vitamin D therapy) must be<br />prescribed, serum calcium levels should be monitored and calcium dosage adjusted accordingly;<br />Carbamazepine: concomitant use of carbamazepine and hydrochlorothiazide has been associated with<br />the risk of symptomatic hyponatraemia. Electrolytes should be monitored during concomitant use. If<br />possible, another class of diuretics should be used;<br />Other interactions: the hyperglycaemic effect of beta-blockers and diazoxide may be enhanced by<br />thiazides. Anticholinergic agents (e.g. atropine, beperiden) may increase the bioavailability of<br />thiazide-type diuretics by decreasing gastrointestinal motility and stomach emptying rate. Thiazides<br />may increase the risk of adverse effects caused by amantadine. Thiazides may reduce the renal&nbsp;excretion of cytotoxic medicinal products (e.g. cyclophosphamide, methotrexate) and potentiate their<br />myelosuppressive effects.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />Angiotensin II Receptor Antagonists (AIIRAs)</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td>The use of AIIRAs is not recommended during the first trimester of pregnancy (see section 4.4). The<br />use of AIIRAs is contraindicated during the second and third trimesters of pregnancy (see sections 4.3<br />and 4.4).</td></tr></tbody></table><p>Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors<br />during the first trimester of pregnancy has not been conclusive; however a small increase in risk<br />cannot be excluded. Whilst there is no controlled epidemiological data on the risk with Angiotensin II<br />Receptor Antagonists (AIIRAs), similar risks may exist for this class of drugs. Unless continued<br />AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative<br />antihypertensive treatments which have an established safety profile for use in pregnancy. When<br />pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate,<br />alternative therapy should be started.<br />Exposure to AIIRA therapy during the second and third trimesters is known to induce human<br />foetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal<br />toxicity (renal failure, hypotension, hyperkalaemia). (See section 5.3).<br />Should exposure to AIIRAs have occurred from the second trimester of pregnancy, ultrasound check<br />of renal function and skull is recommended.<br />Infants whose mothers have taken AIIRAs should be closely observed for hypotension (see<br />sections 4.3 and 4.4).<br />Hydrochlorothiazide<br />There is limited experience with hydrochlorothiazide during pregnancy, especially during the first<br />trimester. Animal studies are insufficient. Hydrochlorothiazide crosses the placenta. Based on the<br />pharmacological mechanism of action of hydrochlorothiazide its use during the second and third<br />trimester may compromise foeto-placental perfusion and may cause foetal and neonatal effects like<br />icterus, disturbance of electrolyte balance and thrombocytopenia.<br />Hydrochlorothiazide should not be used for gestational oedema, gestational hypertension or<br />preeclampsia due to the risk of decreased plasma volume and placental hypoperfusion, without a<br />beneficial effect on the course of the disease.<br />Hydrochlorothiazide should not be used for essential hypertension in pregnant women except in rare<br />situations where no other treatment could be used.<br />Since CoAprovel contains hydrochlorothiazide, it is not recommended during the first trimester of<br />pregnancy. A switch to a suitable alternative treatment should be carried out in advance of a planned<br />pregnancy.<br />Breast-feeding<br />Angiotensin II Receptor Antagonists (AIIRAs)</p><p>Because no information is available regarding the use of CoAprovel during breast-feeding, CoAprovel<br />is not recommended and alternative treatments with better established safety profiles during breastfeeding<br />are preferable, especially while nursing a newborn or preterm infant.<br />It is unknown whether irbesartan or its metabolites are excreted in human milk.<br />Available pharmacodynamic/toxicological data in rats have shown excretion of irbesartan or its<br />metabolites in milk (for details see 5.3).<br />Hydrochlorothiazide<br />Hydrochlorothiazide is excreted in human milk in small amounts. Thiazides in high doses causing<br />intense diuresis can inhibit the milk production. The use of CoAprovel during breast feeding is not<br />recommended. If CoAprovel is used during breast feeding, doses should be kept as low as possible.<br />Fertility<br />Irbesartan had no effect upon fertility of treated rats and their offspring up to the dose levels inducing<br />the first signs of parental toxicity (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Based on its pharmacodynamic properties, CoAprovel is unlikely to affect the ability to drive and use<br />machines. When driving vehicles or operating machines, it should be taken into account that<br />occasionally dizziness or weariness may occur during treatment of hypertension.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Irbesartan/hydrochlorothiazide combination<br />Among 898 hypertensive patients who received various doses of irbesartan/hydrochlorothiazide<br />(range: 37.5 mg/6.25 mg to 300 mg/25 mg) in placebo-controlled trials, 29.5% of the patients<br />experienced adverse reactions. The most commonly reported ADRs were dizziness (5.6%), fatigue<br />(4.9%), nausea/vomiting (1.8%), and abnormal urination (1.4%). In addition, increases in blood urea<br />nitrogen (BUN) (2.3%), creatine kinase (1.7%) and creatinine (1.1%) were also commonly observed in<br />the trials.<br />Table 1 gives the adverse reactions observed from spontaneous reporting and in placebo-controlled<br />trials.<br />The frequency of adverse reactions listed below is defined using the following convention:<br />very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare<br />(&ge; 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000). Within each frequency grouping, undesirable effects<br />are presented in order of decreasing seriousness.</p><p>Table 1: Adverse Reactions in Placebo-Controlled Trials and Spontaneous Reports<br />Investigations: Common: increases in blood urea nitrogen (BUN),<br />creatinine and creatine kinase<br />Uncommon: decreases in serum potassium and sodium<br />Cardiac disorders: Uncommon: syncope, hypotension, tachycardia, oedema<br />Nervous system disorders: Common: dizziness<br />Uncommon: orthostatic dizziness<br />Not known: headache<br />Ear and labyrinth disorders: Not known: tinnitus<br />Respiratory, thoracic and<br />mediastinal disorders:<br />Not known: cough<br />Gastrointestinal disorders: Common: nausea/vomiting</p><p>Uncommon: diarrhoea<br />Not known: dyspepsia, dysgeusia<br />Renal and urinary disorders: Common: abnormal urination<br />Not known: impaired renal function including isolated<br />cases of renal failure in patients at risk (see<br />section 4.4)<br />Musculoskeletal and connective<br />tissue disorders:<br />Uncommon: swelling extremity<br />Not known: arthralgia, myalgia<br />Metabolism and nutrition<br />disorders:<br />Not known: hyperkalaemia<br />Vascular disorders: Uncommon: flushing<br />General disorders and<br />administration site conditions:<br />Common: fatigue<br />Immune system disorders: Not known: cases of hypersensitivity reactions such as<br />angioedema, rash, urticaria<br />Hepatobiliary disorders: Uncommon:<br />Not known:<br />jaundice<br />hepatitis, abnormal liver function<br />Reproductive system and breast<br />disorders:<br />Uncommon: sexual dysfunction, libido changes<br />Additional information on individual components: in addition to the adverse reactions listed above for<br />the combination product, other adverse reactions previously reported with one of the individual<br />components may be potential adverse reactions with CoAprovel. Tables 2 and 3 below detail the<br />adverse reactions reported with the individual components of CoAprovel.<br />Table 2: Adverse reactions reported with the use of irbesartan alone<br />Blood and lymphatic system<br />disorders:<br />Not known: thrombocytopenia<br />General disorders and<br />administration site conditions:<br />Uncommon: chest pain<br />Immune system disorders: Not known: Anaphylactic reaction including anaphylactic<br />shock<br />Table 3: Adverse reactions reported with the use of hydrochlorothiazide alone<br />Investigations: Not known: electrolyte imbalance (including hypokalaemia<br />and hyponatraemia, see section 4.4),<br />hyperuricaemia, glycosuria, hyperglycaemia,<br />increases in cholesterol and triglycerides<br />Cardiac disorders: Not known: cardiac arrhythmias<br />Blood and lymphatic system<br />disorders:<br />Not known: aplastic anaemia, bone marrow depression,<br />neutropenia/agranulocytosis, haemolytic<br />anaemia, leucopenia, thrombocytopenia<br />Nervous system disorders: Not known: vertigo, paraesthesia, light-headedness,<br />restlessness<br />Eye disorders: Not known: transient blurred vision, xanthopsia, acute<br />myopia and secondary acute angle-closure<br />glaucoma<br />Respiratory, thoracic and<br />mediastinal disorders:<br />Not known: respiratory distress (including pneumonitis and<br />pulmonary oedema)<br />Gastrointestinal disorders: Not known: pancreatitis, anorexia, diarrhoea, constipation,<br />gastric irritation, sialadenitis, loss of appetite<br />Renal and urinary disorders: Not known: interstitial nephritis, renal dysfunction<br />Skin and subcutaneous tissue<br />disorders:<br />Not known: anaphylactic reactions, toxic epidermal<br />necrolysis, necrotizing angitis (vasculitis,<br />cutaneous vasculitis), cutaneous lupus</p><p>erythematosus-like reactions, reactivation of<br />cutaneous lupus erythematosus,<br />photosensitivity reactions, rash, urticaria<br />Musculoskeletal and connective<br />tissue disorders:<br />Not known: weakness, muscle spasm<br />Vascular disorders: Not known: postural hypotension<br />General disorders and<br />administration site conditions:<br />Not known: fever<br />Hepatobiliary disorders: Not known: jaundice (intrahepatic cholestatic jaundice)<br />Psychiatric disorders: Not known: depression, sleep disturbances<br />Neoplasms benign, malignant<br />and unspecified (incl cysts and<br />polyps)<br />Not known: non-melanoma skin cancer (basal cell<br />carcinoma and squamous cell carcinoma)<br />Non-melanoma skin cancer: Based on available data from epidemiological studies, cumulative dose dependent association<br />between HCTZ and NMSC has been observed (see also sections 4.4 and 5.1).</p><p>The dose dependent adverse events of hydrochlorothiazide (particularly electrolyte disturbances) may<br />increase when titrating the hydrochlorothiazide.<br />Reporting of suspected adverse reactions<br />Reporting of side effects:<br />The National Pharmacovigilance and Drug Safety Centre<br />(NPC) Fax: +966-11-205-7662<br />Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340. Toll free phone:<br />8002490000 E-mail:<br />npc.drug@sfda.gov.sa<br />Website:<br />www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No specific information is available on the treatment of overdose with CoAprovel. The patient should<br />be closely monitored, and the treatment should be symptomatic and supportive. Management depends<br />on the time since ingestion and the severity of the symptoms. Suggested measures include induction<br />of emesis and/or gastric lavage. Activated charcoal may be useful in the treatment of overdose. Serum<br />electrolytes and creatinine should be monitored frequently. If hypotension occurs, the patient should<br />be placed in a supine position, with salt and volume replacements given quickly.<br />The most likely manifestations of irbesartan overdose are expected to be hypotension and tachycardia;<br />bradycardia might also occur.<br />Overdose with hydrochlorothiazide is associated with electrolyte depletion (hypokalaemia,<br />hypochloremia, hyponatraemia) and dehydration resulting from excessive diuresis. The most common<br />signs and symptoms of overdose are nausea and somnolence. Hypokalaemia may result in muscle<br />spasms and/or accentuate cardiac arrhythmias associated with the concomitant use of digitalis<br />glycosides or certain anti-arrhythmic medicinal products.<br />Irbesartan is not removed by haemodialysis. The degree to which hydrochlorothiazide is removed by<br />haemodialysis has not been established.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: angiotensin-II antagonists, combinations<br />ATC code: C09DA04.</p><p>Mechanism of action</p><p>CoAprovel is a combination of an angiotensin-II receptor antagonist, irbesartan, and a thiazide<br />diuretic, hydrochlorothiazide. The combination of these ingredients has an additive antihypertensive<br />effect, reducing blood pressure to a greater degree than either component alone.<br />Irbesartan is a potent, orally active, selective angiotensin-II receptor (AT1 subtype) antagonist. It is<br />expected to block all actions of angiotensin-II mediated by the AT1 receptor, regardless of the source<br />or route of synthesis of angiotensin-II. The selective antagonism of the angiotensin-II (AT1) receptors<br />results in increases in plasma renin levels and angiotensin-II levels, and a decrease in plasma<br />aldosterone concentration. Serum potassium levels are not significantly affected by irbesartan alone at<br />the recommended doses in patients without risk of electrolyte imbalance (see sections 4.4 and 4.5).<br />Irbesartan does not inhibit ACE (kininase-II), an enzyme which generates angiotensin-II and also<br />degrades bradykinin into inactive metabolites. Irbesartan does not require metabolic activation for its<br />activity.<br />Hydrochlorothiazide is a thiazide diuretic. The mechanism of antihypertensive effect of thiazide<br />diuretics is not fully known. Thiazides affect the renal tubular mechanisms of electrolyte reabsorption,<br />directly increasing excretion of sodium and chloride in approximately equivalent amounts. The<br />diuretic action of hydrochlorothiazide reduces plasma volume, increases plasma renin activity,<br />increases aldosterone secretion, with consequent increases in urinary potassium and bicarbonate loss,<br />and decreases in serum potassium. Presumably through blockade of the renin-angiotensin-aldosterone<br />system, co-administration of irbesartan tends to reverse the potassium loss associated with these<br />diuretics. With hydrochlorothiazide, onset of diuresis occurs in 2 hours, and peak effect occurs at<br />about 4 hours, while the action persists for approximately 6-12 hours.<br />The combination of hydrochlorothiazide and irbesartan produces dose-related additive reductions in<br />blood pressure across their therapeutic dose ranges. The addition of 12.5 mg hydrochlorothiazide to<br />300 mg irbesartan once daily in patients not adequately controlled on 300 mg irbesartan alone resulted<br />in further placebo-corrected diastolic blood pressure reductions at trough (24 hours post-dosing) of<br />6.1 mm Hg. The combination of 300 mg irbesartan and 12.5 mg hydrochlorothiazide resulted in an<br />overall placebo-subtracted systolic/diastolic reductions of up to 13.6/11.5 mm Hg.<br />Limited clinical data (7 out of 22 patients) suggest that patients not controlled with the<br />300 mg/12.5 mg combination may respond when uptitrated to 300 mg/25 mg. In these patients, an<br />incremental blood pressure lowering effect was observed for both systolic blood pressure (SBP) and<br />diastolic blood pressure (DBP) (13.3 and 8.3 mm Hg, respectively).<br />Once daily dosing with 150 mg irbesartan and 12.5 mg hydrochlorothiazide gave systolic/diastolic<br />mean placebo-adjusted blood pressure reductions at trough (24 hours post-dosing) of 12.9/6.9 mm Hg<br />in patients with mild-to-moderate hypertension. Peak effects occurred at 3-6 hours. When assessed by<br />ambulatory blood pressure monitoring, the combination 150 mg irbesartan and 12.5 mg<br />hydrochlorothiazide once daily produced consistent reduction in blood pressure over the 24 hours<br />period with mean 24-hour placebo-subtracted systolic/diastolic reductions of 15.8/10.0 mm Hg. When<br />measured by ambulatory blood pressure monitoring, the trough to peak effects of<br />CoAprovel 150 mg/12.5 mg were 100%. The trough to peak effects measured by cuff during office<br />visits were 68% and 76% for CoAprovel 150 mg/12.5 mg and CoAprovel 300 mg/12.5 mg,<br />respectively. These 24-hour effects were observed without excessive blood pressure lowering at peak<br />and are consistent with safe and effective blood-pressure lowering over the once-daily dosing interval.<br />In patients not adequately controlled on 25 mg hydrochlorothiazide alone, the addition of irbesartan<br />gave an added placebo-subtracted systolic/diastolic mean reduction of 11.1/7.2 mm Hg.<br />The blood pressure lowering effect of irbesartan in combination with hydrochlorothiazide is apparent<br />after the first dose and substantially present within 1-2 weeks, with the maximal effect occurring by 6-<br />8 weeks. In long-term follow-up studies, the effect of irbesartan/hydrochlorothiazide was maintained<br />for over one year. Although not specifically studied with the CoAprovel, rebound hypertension has not<br />been seen with either irbesartan or hydrochlorothiazide.</p><p>The effect of the combination of irbesartan and hydrochlorothiazide on morbidity and mortality has<br />not been studied. Epidemiological studies have shown that long term treatment with<br />hydrochlorothiazide reduces the risk of cardiovascular mortality and morbidity.<br />There is no difference in response to CoAprovel, regardless of age or gender. As is the case with other<br />medicinal products that affect the renin-angiotensin system, black hypertensive patients have notably<br />less response to irbesartan monotherapy. When irbesartan is administered concomitantly with a low<br />dose of hydrochlorothiazide (e.g. 12.5 mg daily), the antihypertensive response in black patients<br />approaches that of non-black patients.<br />Clinical efficacy and safety<br />Efficacy and safety of CoAprovel as initial therapy for severe hypertension (defined as SeDBP<br />&ge; 110 mmHg) was evaluated in a multicentre, randomized, double-blind, active-controlled, 8-week,<br />parallel-arm study. A total of 697 patients were randomized in a 2:1 ratio to either<br />irbesartan/hydrochlorothiazide 150 mg/12.5 mg or to irbesartan 150 mg and systematically forcetitrated<br />(before assessing the response to the lower dose) after one week to<br />irbesartan/hydrochlorothiazide 300 mg/25 mg or irbesartan 300 mg, respectively.<br />The study recruited 58% males. The mean age of patients was 52.5 years, 13% were &ge; 65 years of age,<br />and just 2% were &ge; 75 years of age. Twelve percent (12%) of patients were diabetic, 34% were<br />hyperlipidemic and the most frequent cardiovascular condition was stable angina pectoris in 3.5% of<br />the participants.<br />The primary objective of this study was to compare the proportion of patients whose SeDBP was<br />controlled (SeDBP &lt; 90 mmHg) at Week 5 of treatment. Forty-seven percent (47.2%) of patients on<br />the combination achieved trough SeDBP &lt; 90 mmHg compared to 33.2% of patients on irbesartan<br />(p = 0.0005). The mean baseline blood pressure was approximately 172/113 mmHg in each treatment<br />group and decreases of SeSBP/SeDBP at five weeks were 30.8/24.0 mmHg and 21.1/19.3 mmHg for<br />irbesartan/hydrochlorothiazide and irbesartan, respectively (p &lt; 0.0001).<br />The types and incidences of adverse events reported for patients treated with the combination were<br />similar to the adverse event profile for patients on monotherapy. During the 8-week treatment period,<br />there were no reported cases of syncope in either treatment group. There were 0.6% and 0% of patients<br />with hypotension and 2.8% and 3.1% of patients with dizziness as adverse reactions reported in the<br />combination and monotherapy groups, respectively.<br />Dual blockade of the renin-angiotensin-aldosterone system (RAAS)<br />Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in<br />combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs<br />Nephropathy in Diabetes)) have examined the use of the combination of an ACE-inhibitor with an<br />angiotensin II receptor blocker. ONTARGET was a study conducted in patients with a history of<br />cardiovascular or cerebrovascular disease, or type 2 diabetes mellitus accompanied by evidence of<br />end-organ damage. VA NEPHRON-D was a study in patients with type 2 diabetes mellitus and<br />diabetic nephropathy.<br />These studies have shown no significant beneficial effect on renal and/or cardiovascular outcomes and<br />mortality, while an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as<br />compared to monotherapy was observed. Given their similar pharmacodynamic properties, these<br />results are also relevant for other ACE-inhibitors and angiotensin II receptor blockers.<br />ACE-inhibitors and angiotensin II receptor blockers should therefore not be used concomitantly in<br />patients with diabetic nephropathy.</p><p>ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints)<br />was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE-inhibitor<br />or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney<br />disease, cardiovascular disease, or both. The study was terminated early because of an increased risk<br />of adverse outcomes. Cardiovascular death and stroke were both numerically more frequent in the<br />aliskiren group than in the placebo group and adverse events and serious adverse events of interest<br />(hyperkalaemia, hypotension and renal dysfunction) were more frequently reported in the aliskiren<br />group than in the placebo group.<br />Non-melanoma skin cancer:<br />Based on available data from epidemiological studies, cumulative dosedependent association between<br />HCTZ and NMSC has been observed. One study included a population comprised of 71,533 cases of<br />BCC and of 8,629 cases of SCC matched to 1,430,833 and 172,462 population controls, respectively.<br />High HCTZ use (&ge;50,000 mg cumulative) was associated with an adjusted OR of 1.29 (95% CI: 1.23-<br />1.35) for BCC and 3.98 (95% CI: 3.68-4.31) for SCC. A clear cumulative dose response relationship<br />was observed for both BCC and SCC. Another study showed a possible association between lip cancer<br />(SCC) and exposure to HCTZ: 633 cases of lip-cancer were matched with 63,067 population controls,<br />using a risk-set sampling strategy. A cumulative dose-response relationship was demonstrated with an<br />adjusted OR 2.1 (95% CI: 1.7-2.6) increasing to OR 3.9 (3.0-4.9) for high use (~25,000 mg) and OR<br />7.7 (5.7-10.5) for the highest cumulative dose (~100,000 mg) (see also section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Concomitant administration of hydrochlorothiazide and irbesartan has no effect on the<br />pharmacokinetics of either medicinal product.<br />Absorption<br />Irbesartan and hydrochlorothiazide are orally active agents and do not require biotransformation for<br />their activity. Following oral administration of CoAprovel, the absolute oral bioavailability is 60-80%<br />and 50-80% for irbesartan and hydrochlorothiazide, respectively. Food does not affect the<br />bioavailability of CoAprovel. Peak plasma concentration occurs at 1.5-2 hours after oral<br />administration for irbesartan and 1-2.5 hours for hydrochlorothiazide.<br />Distribution<br />Plasma protein binding of irbesartan is approximately 96%, with negligible binding to cellular blood<br />components. The volume of distribution for irbesartan is 53-93 litres. Hydrochlorothiazide is 68%<br />protein-bound in the plasma, and its apparent volume of distribution is 0.83-1.14 l/kg.<br />Linearity/non-linearity<br />Irbesartan exhibits linear and dose proportional pharmacokinetics over the dose range of 10 to 600 mg.<br />A less than proportional increase in oral absorption at doses beyond 600 mg was observed; the<br />mechanism for this is unknown. The total body and renal clearance are 157-176 and 3.0-3.5 ml/min,<br />respectively. The terminal elimination half-life of irbesartan is 11-15 hours. Steady-state plasma<br />concentrations are attained within 3 days after initiation of a once-daily dosing regimen. Limited<br />accumulation of irbesartan (&lt; 20%) is observed in plasma upon repeated once-daily dosing. In a study,<br />somewhat higher plasma concentrations of irbesartan were observed in female hypertensive patients.<br />However, there was no difference in the half-life and accumulation of irbesartan. No dosage<br />adjustment is necessary in female patients. Irbesartan AUC and Cmax values were also somewhat<br />greater in older subjects (&ge; 65 years) than those of young subjects (18-40 years). However the terminal<br />half-life was not significantly altered. No dosage adjustment is necessary in older people. The mean<br />plasma half-life of hydrochlorothiazide reportedly ranges from 5-15 hours.<br />Biotransformation</p><p>Following oral or intravenous administration of 14C irbesartan, 80-85% of the circulating plasma<br />radioactivity is attributable to unchanged irbesartan. Irbesartan is metabolised by the liver via<br />glucuronide conjugation and oxidation. The major circulating metabolite is irbesartan glucuronide<br />(approximately 6%). In vitro studies indicate that irbesartan is primarily oxidised by the<br />cytochrome P450 enzyme CYP2C9; isoenzyme CYP3A4 has negligible effect.<br />Elimination<br />Irbesartan and its metabolites are eliminated by both biliary and renal pathways. After either oral or<br />intravenous administration of 14C irbesartan, about 20% of the radioactivity is recovered in the urine,<br />and the remainder in the faeces. Less than 2% of the dose is excreted in the urine as unchanged<br />irbesartan. Hydrochlorothiazide is not metabolized but is eliminated rapidly by the kidneys. At least<br />61% of the oral dose is eliminated unchanged within 24 hours. Hydrochlorothiazide crosses the<br />placental but not the blood-brain barrier, and is excreted in breast milk.<br />Renal impairment<br />In patients with renal impairment or those undergoing haemodialysis, the pharmacokinetic parameters<br />of irbesartan are not significantly altered. Irbesartan is not removed by haemodialysis. In patients with<br />creatinine clearance &lt; 20 ml/min, the elimination half-life of hydrochlorothiazide was reported to<br />increase to 21 hours.<br />Hepatic impairment<br />In patients with mild to moderate cirrhosis, the pharmacokinetic parameters of irbesartan are not<br />significantly altered. Studies have not been performed in patients with severe hepatic impairment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Irbesartan/hydrochlorothiazide<br />The potential toxicity of the irbesartan/hydrochlorothiazide combination after oral administration was<br />evaluated in rats and macaques in studies lasting up to 6 months. There were no toxicological findings<br />observed of relevance to human therapeutic use.<br />The following changes, observed in rats and macaques receiving the irbesartan/hydrochlorothiazide<br />combination at 10/10 and 90/90 mg/kg/day, were also seen with one of the two medicinal products<br />alone and/or were secondary to decreases in blood pressure (no significant toxicologic interactions<br />were observed):<br /> kidney changes, characterized by slight increases in serum urea and creatinine, and<br />hyperplasia/hypertrophy of the juxtaglomerular apparatus, which are a direct consequence of the<br />interaction of irbesartan with the renin-angiotensin system;<br /> slight decreases in erythrocyte parameters (erythrocytes, haemoglobin, haematocrit);<br /> stomach discoloration, ulcers and focal necrosis of gastric mucosa were observed in few rats in a<br />6 months toxicity study at irbesartan 90 mg/kg/day, hydrochlorothiazide 90 mg/kg/day, and<br />irbesartan/hydrochlorothiazide 10/10 mg/kg/day. These lesions were not observed in macaques;<br /> decreases in serum potassium due to hydrochlorothiazide and partly prevented when<br />hydrochlorothiazide was given in combination with irbesartan.<br />Most of the above mentioned effects appear to be due to the pharmacological activity of irbesartan<br />(blockade of angiotensin-II-induced inhibition of renin release, with stimulation of the renin-producing<br />cells) and occur also with angiotensin converting enzyme inhibitors. These findings appear to have no<br />relevance to the use of therapeutic doses of irbesartan/hydrochlorothiazide in humans.<br />No teratogenic effects were seen in rats given irbesartan and hydrochlorothiazide in combination at<br />doses that produced maternal toxicity. The effects of the irbesartan/hydrochlorothiazide combination<br />on fertility have not been evaluated in animal studies, as there is no evidence of adverse effect on<br />fertility in animals or humans with either irbesartan or hydrochlorothiazide when administered alone.</p><p>However, another angiotensin-II antagonist affected fertility parameters in animal studies when given<br />alone. These findings were also observed with lower doses of this other angiotensin-II antagonist when<br />given in combination with hydrochlorothiazide.<br />There was no evidence of mutagenicity or clastogenicity with the irbesartan/hydrochlorothiazide<br />combination. The carcinogenic potential of irbesartan and hydrochlorothiazide in combination has not<br />been evaluated in animal studies.<br />Irbesartan<br />There was no evidence of abnormal systemic or target organ toxicity at clinically relevant doses. In<br />non-clinical safety studies, high doses of irbesartan (&ge; 250 mg/kg/day in rats and &ge; 100 mg/kg/day in<br />macaques) caused a reduction of red blood cell parameters (erythrocytes, haemoglobin, haematocrit).<br />At very high doses (&ge; 500 mg/kg/day) degenerative changes in the kidneys (such as interstitial<br />nephritis, tubular distention, basophilic tubules, increased plasma concentrations of urea and<br />creatinine) were induced by irbesartan in the rat and the macaque and are considered secondary to the<br />hypotensive effects of the medicinal product which led to decreased renal perfusion. Furthermore,<br />irbesartan induced hyperplasia/hypertrophy of the juxtaglomerular cells (in rats at &ge; 90 mg/kg/day, in<br />macaques at &ge; 10 mg/kg/day). All of these changes were considered to be caused by the<br />pharmacological action of irbesartan. For therapeutic doses of irbesartan in humans, the<br />hyperplasia/hypertrophy of the renal juxtaglomerular cells does not appear to have any relevance.<br />There was no evidence of mutagenicity, clastogenicity or carcinogenicity.<br />Fertility and reproductive performance were not affected in studies of male and female rats even at<br />oral doses of irbesartan causing some parental toxicity (from 50 to 650 mg/kg/day), including<br />mortality at the highest dose. No significant effects on the number of corpora lutea, implants, or live<br />foetuses were observed. Irbesartan did not affect survival, development, or reproduction of offspring.<br />Studies in animals indicate that the radiolabelled irbesartan is detected in rat and rabbit foetuses.<br />Irbesartan is excreted in the milk of lactating rats.<br />Animal studies with irbesartan showed transient toxic effects (increased renal pelvic cavitation,<br />hydroureter or subcutaneous oedema) in rat foetuses, which were resolved after birth. In rabbits,<br />abortion or early resorption was noted at doses causing significant maternal toxicity, including<br />mortality. No teratogenic effects were observed in the rat or rabbit.<br />Hydrochlorothiazide<br />Although equivocal evidence for a genotoxic or carcinogenic effect was found in some experimental<br />models, the extensive human experience with hydrochlorothiazide has failed to show an association<br />between its use and an increase in neoplasms.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Microcrystalline cellulose<br />Croscarmellose sodium<br />Lactose monohydrate<br />Magnesium stearate<br />Colloidal hydrated silica<br />Pregelatinised maize starch<br />Red and yellow ferric oxides (E172)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.<br />Store in the original package in order to protect from moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cartons of 14 tablets in PVC/PVDC/Aluminium blisters.<br />Cartons of 28 tablets in PVC/PVDC/Aluminium blisters.<br />Cartons of 56 tablets in PVC/PVDC/Aluminium blisters.<br />Cartons of 98 tablets in PVC/PVDC/Aluminium blisters.<br />Cartons of 56 x 1 tablets in PVC/PVDC/Aluminium perforated unit dose blisters.<br />Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local<br />requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sanofi Clir SNC
54, rue La Boétie
F-75008 Paris - France
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                October 2018
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>